Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $7.6 million.

  • Benitec Biopharma's Total Liabilities rose 11831.95% to $7.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.6 million, marking a year-over-year increase of 11831.95%. This contributed to the annual value of $5.0 million for FY2024, which is 1642.42% up from last year.
  • As of Q1 2025, Benitec Biopharma's Total Liabilities stood at $7.6 million, which was up 11831.95% from $3.1 million recorded in Q4 2024.
  • Over the past 5 years, Benitec Biopharma's Total Liabilities peaked at $7.6 million during Q1 2025, and registered a low of $1.4 million during Q2 2021.
  • Over the past 5 years, Benitec Biopharma's median Total Liabilities value was $3.5 million (recorded in 2024), while the average stood at $3.7 million.
  • As far as peak fluctuations go, Benitec Biopharma's Total Liabilities skyrocketed by 25828.64% in 2021, and later tumbled by 4684.68% in 2024.
  • Over the past 5 years, Benitec Biopharma's Total Liabilities (Quarter) stood at $3.2 million in 2021, then fell by 8.4% to $2.9 million in 2022, then surged by 102.1% to $5.9 million in 2023, then plummeted by 46.85% to $3.1 million in 2024, then skyrocketed by 144.29% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q1 2025, $3.1 million for Q4 2024, and $4.6 million during Q3 2024.